Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Systemic antibody responses to gut commensal bacteria: How and why do I know you?Journal of Allergy and Clinical Immunology.  143:1353-1354. 2019
2018 Expanded TCRβ CDR3 clonotypes distinguish Crohn’s disease and ulcerative colitis patientsMucosal Immunology.  11:1487-1495. 2018
2017 Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel DiseaseGastroenterology.  152:206-217.e2. 2017
2015 Characterization of Genetic Loci That Affect Susceptibility to Inflammatory Bowel Diseases in African AmericansGastroenterology.  149:1575-1586. 2015
2015 Human seroreactivity to gut microbiota antigensJournal of Allergy and Clinical Immunology.  136:1378-1386.e5. 2015
2015 Human gastric epithelial cells contribute to gastric immune regulation by providing retinoic acid to dendritic cellsMucosal Immunology.  8:533-544. 2015
2014 Body Mass Index Is Associated With Mucosal Disease in Crohn's: Results of a Case-Control Study.Gastroenterology Research.  7:111-117. 2014
2014 IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitisGut.  63:1728-1736. 2014
2014 The microbiota, the immune system and the allograftAmerican Journal of Transplantation.  14:1236-1248. 2014
2013 Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine.  369:699-710. 2013
2013 Interleukin 13 and its role in gut defence and inflammationPostgraduate Medical Journal.  89:448-456. 2013
2013 Helicobacter pylori infection inhibits phagocyte clearance of apoptotic gastric epithelial cellsJournal of Immunology.  190:6626-6634. 2013
2013 Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: An open-label, multicenter, prospective trialInflammatory Bowel Diseases.  19:293-300. 2013
2012 Interleukin 13 and its role in gut defence and inflammationGut.  61:1765-1773. 2012
2012 Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitisJournal of Immunology.  188:6309-6318. 2012
2012 A framework for human microbiome researchNature.  486:215-221. 2012
2012 Structure, function and diversity of the healthy human microbiomeNature.  486:207-214. 2012
2012 Complement-dependent injury and protection in a murine model of acute DSS-induced colitisJournal of Immunology.  188:6309-6318. 2012
2012 Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples.Genome Biology.  13. 2012
2012 Inflammatory bowel diseases: Emerging therapies and promising molecular targetsFrontiers in bioscience (Scholar edition).  4 S:1172-1189. 2012
2012 Structure, function and diversity of the healthy human microbiomeNature.  486:207-214. 2012
2011 Remestemcel-L: Human mesenchymal stem cells as an emerging therapy for Crohn's diseaseExpert Opinion on Biological Therapy.  11:1249-1256. 2011
2011 Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartmentsJournal of Infectious Diseases.  204:309-314. 2011
2011 Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 productionGut.  60:449-455. 2011
2011 The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patientsJournal of Acquired Immune Deficiency Syndromes.  56:340-343. 2011
2011 Environmental Triggers, Genetic Background, and Crohn's DiseaseGastroenterology.  140:363-365. 2011
2010 Human primary gastric dendritic cells induce a Th1 response to H. pyloriMucosal Immunology.  3:260-269. 2010
2010 Cycling of gut mucosal CD4 T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levelsMucosal Immunology.  3:172-181. 2010
2009 Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot studyInflammatory Bowel Diseases.  15:829-836. 2009
2009 Multiple endoscopic biopsies in research subjects: safety results from a National Institutes of Health seriesGastrointestinal Endoscopy.  69:906-910. 2009
2009 Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10- producing T cells and increased lamina propria plasmacytoid dendritic cellsClinical and Experimental Immunology.  155:447-456. 2009
2009 Gut Permeability and ColitisGastroenterology.  137:732-734. 2009
2008 Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapyJournal of Infectious Diseases.  197:714-720. 2008
2008 A Common Barrier Defect for Celiac Disease and Ulcerative ColitisGastroenterology.  135:2145-2147. 2008
2008 Principles underlying the use of immunological therapy in Crohn’s diseaseProceedings of the Falk Foundation2008
2007 Anti-IgE treatment of eosinophil-associated gastrointestinal disordersJournal of Allergy and Clinical Immunology.  120:594-601. 2007
2007 GAIN for loss: Adalimumab for infliximab-refractory Crohn diseaseAnnals of Internal Medicine.  146:888-890. 2007
2007 The fundamental basis of inflammatory bowel diseaseJournal of Clinical Investigation.  117:514-521. 2007
2006 Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibodyInflammatory Bowel Diseases.  12:9-15. 2006
2006 Excess IL-12 but not IL-23 Accompanies the Inflammatory Bowel Disease Associated With Common Variable ImmunodeficiencyGastroenterology.  131:748-756. 2006
2006 Intestinal disease in hermansky-pudlak syndrome: Occurrence of colitis and relation to genotypeClinical Gastroenterology and Hepatology.  4:73-80. 2006
2005 Yet another biologic for Crohn disease: It may be safe, but will it work?Evidence-Based Gastroenterology.  6:46-47. 2005
2005 Anti-interleukin-12 antibody for active Crohn's disease [3] (multiple letters)New England Journal of Medicine.  352:627-628. 2005
2005 Normal gut mucosal immunity: a dynamic balance of tolerance and defenseGastroenterology and Hepatology.  1:50-56. 2005
2004 Anti-interleukin-12 antibody for active Crohn's diseaseNew England Journal of Medicine.  351:2069-2079. 2004
2004 Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.Journal of Clinical Investigation.  113:1490-1497. 2004
2004 Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitisJournal of Clinical Investigation.  113:1490-1497. 2004
2002 Peptide YY as a growth factor for intestinal epitheliumPeptides.  23:383-388. 2002
2000 Peptide YY administration decreases brain aluminum in the Ts65Dn Down syndrome mouse modelGrowth, development, and aging : GDA.  64:3-19. 2000
2000 Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptorBiochemical Journal.  350:655-661. 2000
2000 Primary structures of PYY, [Pro34]PYY, and PYY-(3-36) confer different conformations and receptor selectivityAJP - Gastrointestinal and Liver Physiology.  279. 2000
1999 Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colonRegulatory Peptides.  83:11-19. 1999
1999 Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathwayJournal of Clinical Investigation.  104:1693-1701. 1999
1998 Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2Journal of Clinical Investigation.  102:1994-2001. 1998
1998 Peptide YY inhibits vasopressin-stimulated chloride secretion in inner medullary collecting duct cellsAJP - Renal Physiology.  275. 1998
1998 Peptide YY inhibits vasopressin-stimulated chloride secretion in inner medullary collecting duct cells.American Journal of Physiology.  275:F452-F457. 1998
1998 The neuropeptide Y/Peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cellsBiochemical and Biophysical Research Communications.  246:91-94. 1998
1997 Fxtracellular nucleotides regulate chloride conductance in inner medullary collecting duct cellsFederation proceedings.  11. 1997
1997 Peptide YY inhibits vasopressin stimulated chloride current in inner medullary collecting duct cellsFederation proceedings.  11. 1997
1997 Peptide YY receptor distribution and subtype in the kidney: Effect on renal hemodynamics and function in ratsAJP - Renal Physiology.  273. 1997
1997 Peptide YY receptor distribution and subtype in the kidney: effect on renal hemodynamics and function in rats.AJP - Renal Physiology.  273:F545-F553. 1997
1997 Peptide YY receptor distribution and subtype in the kidney: effect on renal hemodynamics and function in rats.American Journal of Physiology.  273:F545-F553. 1997
1997 Retinoic acid is a negative regulator of the neuropeptide Y/ peptide YY Y1 receptor gene in SK-N-MC cellsJournal of Neurochemistry.  68:20-25. 1997
1997 Total parenteral nutrition alters NPY/PYY receptor levels in the rat brainPhysiology and Behavior.  62:1219-1223. 1997
1996 Distribution of binding sites for thromboxane A2 in the mouse kidney.American Journal of Physiology.  271:F1131-F1138. 1996
1996 Distribution of binding sites for thromboxane a2 in the mouse kidneyAmerican Journal of Physiology.  271. 1996
1996 Renal denervation and the effect of peptide yy on renal blood flow in ratsFederation proceedings.  10. 1996
1996 Localization and characterization of neuropeptide Y/peptide YY receptors in the brain of the smooth dogfish (Mustelis canis)Regulatory Peptides.  61:167-173. 1996
1996 Retinoic acid is a negative regulator of the neuropeptide y/peptide yy y1 receptor gene in sk-n-mc cellsJournal of Investigative Medicine.  44. 1996
1995 Regulation of blood pressure by the type 1A angiotensin II receptor geneProceedings of the National Academy of Sciences.  92:3521-3525. 1995
1995 Diagnostic utility of K-ras mutational analysis on bile obtained by endoscopic retrograde cholangiopancreatographyGastrointestinal Endoscopy.  42:317-320. 1995
1994 Characterization of a Y1-preferring NPY/PYY receptor in HT-29 cellsAmerican Journal of Physiology.  267. 1994
1994 Characterization of a Y1-preferring NPY/PYY receptor in HT-29 cells.American Journal of Physiology.  267:G901-G907. 1994
1994 Some sensory neurons express neuropeptide Y receptors: Potential paracrine inhibition of primary afferent nociceptors following peripheral nerve injuryJournal of Neuroscience.  14:3958-3968. 1994
1994 Characterization of a Y 1 -preferring NPY/PYY receptor in HT-29 cellsAJP - Gastrointestinal and Liver Physiology.  267. 1994
1993 Characterization of peptide YY receptors in rabbit colonic mucosaPeptides.  14:567-572. 1993
1993 Neuropeptide Y/peptide YY receptor binding sites in the heart: Localization and pharmacological characterizationNeuroscience.  53:889-898. 1993
1991 Solubilization of the Neuropeptide Y Receptor from Rat Brain MembranesJournal of Neurochemistry.  56:1804-1809. 1991
1990 Comparison of the Neuropeptide Y Receptor in the Rat Brain and Intestine,Annals of the New York Academy of Sciences.  611:48-57. 1990
1989 Cross-linking of neuropeptide Y to its receptor on rat brain membranes.American Journal of Physiology.  256:G637-G643. 1989
1989 Cross-linking of neuropeptide Y to its receptor on rat brain membranesAmerican Journal of Physiology.  256. 1989
A framework for human microbiome researchNature.  486:215-221.
Vedolizumab as induction and maintenance therapy for Crohn's diseaseNew England Journal of Medicine.  369:711-721.

Chapter

Year Title Altmetric
2017 Briakinumab and ustekinumab: Anti-p40 antibodies for inflammatory bowel disease treatment.  367-373. 2017
2015 Biologic treatment of Crohn’s disease: Briakinumab and Ustekinumab 2015
2012 Immunologic diseases of the gastrointestinal tract.  896-909. 2012
2012 Biologic treatment of crohn's disease: Briakinumab and ustekinumab.  433-440. 2012
2009 Inflammatory Bowel Disease.  231-244. 2009
2004 Effector mechanisms governing experimental mucosal inflammation and human IBD: new targets for anti-cytokine therapy.  156-165. 2004
2003 Peptide YY, pancreatic polypeptide, and neuroped\ptide Y 2003
1994 The pancreatic polypeptide family.  341-370. 1994
1992 Gastrointestinal peptides.  171-204. 1992
1991 Gastrointestinal hormones.  24-60. 1991
1991 Gastrointestinal peptides.  203-230. 1991
1990 Tropical protozoal enteritides.  108-128. 1990

Principal Investigator On

  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2014 - 2019
  • IBD Gene Mapping by Clinical and Population Subset  awarded by Rutgers, the State University of New Jersey 2018 - 2019
  • Private Grant  awarded by Genentech 2014 - 2018
  • Private Grant  awarded by Janssen 2016 - 2017
  • IBD Gene Mapping by Clinical and Population Subset  awarded by JOHNS HOPKINS SCHOOL OF MEDICINE 2012 - 2017
  • Ulcerative Colitis - Regulation of the IL-13 Receptor System  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2013 - 2017
  • Antimicrobial Antibodies as Predictors of Inflammatory Bowel Disease  awarded by MAYO CLINIC 2015 - 2017
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014
  • Private Grant  awarded by ABBOTT LABORATORIES 2013 - 2014
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2014
  • Private Grant  awarded by Centocor 2010 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2013
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2009 - 2013
  • Private Grant  awarded by BIOGEN IDEC, INC. 2008 - 2013
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2013
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2013
  • Multi-Center African American IBD (Inflammatory Bowel Disease) Study (MAAIS)  awarded by JOHNS HOPKINS SCHOOL OF MEDICINE 2011 - 2012
  • IL-13Ralpha1 Expression by Colonic Cells in Human Ulcerative Colitis  awarded by Crohn's & Colitis Foundation of America 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2012
  • Private Grant  awarded by ABBOTT LABORATORIES 2011 - 2012
  • Private Grant  awarded by Janssen Biotech, Inc. 2011 - 2012
  • Private Grant  awarded by Centocor 2010 - 2012
  • Private Grant  awarded by AMGEN, INC. 2011
  • Private Grant  awarded by AMGEN, INC. 2010 - 2011
  • Family Planning and the Impact on Quality of Life for Patients with Inflammatory Bowel Disease  awarded by STRATEGIC CONSULTANTS INTERNATIONAL 2010 - 2011
  • Education And Training

  • Master of Public Health in Epidemiology, University of North Carolina System : Chapel Hill 2000
  • Doctor of Medicine, Boston University 1983
  • Duke University Medical Center, Residency 1986
  • Duke University Medical Center, Postdoctoral Fellowship 1989
  • Johns Hopkins Hospital, Postdoctoral Fellowship 1987
  • Full Name

  • Peter Mannon